Anti-Human Mesothelin (Amatuximab) - 50 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Mesothelin is involved in normal cell adhesion, differentiation, and signal transduction processes1. In cancer, mesothelin is involved in proliferation, cell migration, and inhibition of apoptosis, making mesothelin a target for cancer therapy. Mesothelin binds to the cancer antigen MUC16(CA-125), and this interaction may promote cell adhesion and metastasis.MORAb-009 (Amatuximab) was generated by panning a phage display library created byimmunizing a mouse with mesothelin cDNA on mesothelin-positive cells2, 3. A mouse precursorantibody was identified, isolated, and its affinity optimized by engineering its variable regions toderive SS1 (scFV). The gene encoding mesothelin Fv (SS1 scFv) was then fused with humanIgG1 and kappa regions to form a chimeric antibody. Amatuximab binds mesothelin on the cell surface of ovarian, mesothelioma, and pancreaticcancer cell lines2. Amatuximab also stains neoplastic cells using immunohistochemistrytechniques. Amatuximab is internalized upon binding mesothelin at the cell surface.Additionally, amatuximab enhances antibody-dependent cytotoxicity in mesothelin positivecancer cell lines and inhibits interaction of mesothelin-expressing cells with MUC16-expressingcells. Preliminary epitope mapping shows that Amatuximab binds mesothelin at its aminoterminus.

≥ 5.0 mg/ml

Mesothelin (also known as CAK1) is a cell surface glycoprotein found onnormal mesothelial cells, including pleura, pericardium, fallopian tubes, trachea, and cornea.Mesothelin is overexpressed by cells in mesothelioma, ovarian cancer, pancreatic cancer, acutemyeloid leukemia, and cholangiocarcinoma. Mesothelin has both membrane-bound and solubleforms.